Alzheimer's disease (AD) is a global public health threat that continues to rise as the proportion of the population over the age of 60 rapidly increases. Aging and dementia are both associated with cognitive decline and share some features in terms of structural and functional alterations in neural circuitry. In this review, we attempt to highlight the network perturbations that occur in "typical" aging and emphasize how they may differ from those that manifest in dementia. We focus in particular on neuroimaging studies of the medial temporal lobe (MTL) network, which is involved in episodic memory and is known to change both with age and with AD pathology. We propose a temporal model of structural and functional alterations in the MTL along the aging-dementia continuum. The earliest changes are synaptic in nature and are detectable in particularly vulnerable white matter pathways such as the perforant path. These are followed by structural degradation in the transentorhinal region and subsequently neurodegeneration of the hippocampus as a result of accumulating pathology as well as deafferentation from entorhinal input. We believe that testing this model explicitly is an important direction for future research, particularly in the context of biomarker discovery and clinical trial design.
Introduction
By 2050, almost a third of the world's population will be 60 years or older. The population over 65 is projected to increase to 86.7 million by 2050 (U.S. Census Bureau, Population Estimates and Projections, 2004) . In addition, the risk for developing Alzheimer's disease (AD) increases with age, with people 85 and older facing the highest risk (Brookmeyer et al., 1998 ). An estimated 5.4 million Americans are living with AD today (Alzheimer's Association, 2012). If there is no prevention or treatment discovered, the number of individuals with AD in 2050 could range between 11 and 16 million. Since age is the single most striking risk factor for AD, the rapid increase in the aging population significantly complicates this public health problem and places a strain on the nation's health care system. Indeed, the costs of care for AD in 2012 alone are estimated at $200 billion (Alzheimer's Association, 2012).
Although much of the research conducted on memory loss focuses on AD, aging in the absence of Alzheimer's pathology is itself associated with neurocognitive decline.
Differentiating the mechanisms for neural changes in successful and pathological aging is critical to accurate diagnosis and effective intervention. In order for this discrimination process to be relevant in the therapeutic arena, it must take place early enough before AD pathology has initiated irreversible neurodegenerative processes (i.e., frank cell loss). There is widespread agreement that intervention at this stage is too late, thus providing the impetus for early diagnosis based on biomarkers during the preclinical/asymptomatic stage (Sperling et al., 2011) . During this stage, molecular and synaptic changes take place (thus giving rise to potential biomarker signatures that can be detected using physiological measures), however cognition remains largely intact.
Here, we review evidence from brain imaging studies that may be used to differentiate aging from AD and its prodromal phase, mild cognitive impairment (MCI). In particular, we focus on neural circuitry that is essential for the formation of new declarative memories, as memory is one of the first domains to show change in the course of AD and memory complaints with aging are fairly common. Although we restrict our review to studies of neural circuits in humans using brain imaging techniques such as structural magnetic resonance imaging (MRI), functional MRI (fMRI), and diffusion tensor imaging (DTI), it is worth noting that studies in aged animals and genetic models of AD have contributed much to our understanding of neural circuits underlying age and pathology-related changes in cognition (e.g., see recent reviews by Gallagher and Koh, 2011; Kitazawa et al., 2012) .
